

# UC San Diego

## UC San Diego Previously Published Works

### Title

Multimodal Therapies for the Treatment of Neuropathic Pain: The Role of Lidocaine Patches in Combination Therapy: A Narrative Review

### Permalink

<https://escholarship.org/uc/item/6k63k68c>

### Journal

Pain and Therapy, 14(3)

### ISSN

2193-8237

### Authors

Nalamachu, Srinivas

Mallick-Searle, Theresa

Adler, Jeremy

et al.

### Publication Date

2025-06-01

### DOI

10.1007/s40122-025-00733-7

Peer reviewed



REVIEW

# Multimodal Therapies for the Treatment of Neuropathic Pain: The Role of Lidocaine Patches in Combination Therapy: A Narrative Review

Srinivas Nalamachu<sup>1</sup> · Theresa Mallick-Searle · Jeremy Adler · Elaine K. Chan · Wendy Borgersen · Dmitri Lissin

Received: December 2, 2024 / Accepted: March 18, 2025 / Published online: April 8, 2025  
© The Author(s) 2025

## ABSTRACT

Neuropathic pain (NP) has a population presence of up to 10%. Both systemic agents and topical agents are recommended as first-line therapy for the treatment of NP but monotherapy provides adequate pain relief only in <50% of the cases. This has created the need for multimodal combination therapy, a practice that is becoming more common. Combination therapy with multiple systemic agents has a risk for drug–drug interactions and adverse events

**Prior Presentation:** Some of the material in this article was presented in poster form at the PAINWeek 2023 Conference in Las Vegas, NV. The poster is available online at: <https://www.scilexholding.com/wp-content/uploads/2023/09/PainWEEK-2023-poster-multimodal-neuropathic-pain-9.1.23.pdf>.

S. Nalamachu  
Analgesic Clinical Research, LLC, Overland Park, KS, USA

T. Mallick-Searle  
Stanford Healthcare, Stanford, CA, USA

J. Adler  
Pacific Pain Medicine Consultants, Oceanside, CA, USA

E. K. Chan · W. Borgersen · D. Lissin (✉)  
Scilex Holding Company, 960 San Antonio Road,  
Palo Alto, CA 94303, USA  
e-mail: [dlissin@scilexholding.com](mailto:dlissin@scilexholding.com)

(AEs), while add-on therapy with a topical agent such as lidocaine patches minimizes such risks. The focus of this review was to find if there is evidence from trials that combination therapy of the topical lidocaine patches with systemic agents will have better efficacy and/or less risk of AEs than the combination of two systemic agents. Since gabapentinoids are one of the most common systemic agents used in first-line NP therapy, the objective of this review was to summarize the safety and efficacy data and evaluate the benefit–risk ratio from three gabapentinoid combinations; gabapentinoid plus opioids, gabapentinoid plus antidepressants, and gabapentinoid plus topical lidocaine patches. Reviews of clinical trials of combinations of gabapentinoids plus other systemic agents (opioids or antidepressants) were associated with increased AEs and dropouts while improvement in analgesic efficacy was inconsistent. Clinical trials where the patients were provided topical lidocaine patches when their first treatment with a gabapentinoid was inadequate demonstrated improved analgesic efficacy with minimal additional AEs. This led to the conclusion that topical lidocaine patches—associated with minimal systemic adverse effects and proven benefits in various neuropathic pain (NP) conditions—can enhance the likelihood of achieving meaningful pain relief when used as adjuvant therapy for NP.

**Keywords:** Combination therapy; Diabetic peripheral neuropathy; Gabapentinoids; Lidocaine patch; Multimodal therapy; Neuropathic pain; Postherpetic neuralgia; Topical analgesics; Topical patch

### Key Summary Points

Monotherapy for neuropathic pain (NP) provides adequate pain relief only in <50% of cases, creating the need for multimodal combination therapy.

Combination therapy with multiple systemic agents has a risk for drug–drug interactions and adverse events (AEs), while add-on therapy with lidocaine patches minimizes such risks.

Combinations of systemic agents (gabapentinoid plus opioid or antidepressant) were associated with increased AEs and dropouts while improvement in analgesic efficacy was inconsistent.

The clinical trials reviewed here have demonstrated that the combination of systemic gabapentinoids plus topical lidocaine patches improve analgesic efficacy with minimal additional AEs.

Lidocaine patches can improve the likelihood of achieving meaningful pain relief when used as adjuvant therapy.

## INTRODUCTION

Neuropathic pain is pain arising as a direct consequence of a lesion or disease affecting the somatosensory system [1]. Clinical manifestations of NP include burning, tingling, numbness, electric shocks, itching, and intolerance to temperature [2]. It arises secondarily to many different underlying conditions and can be classified as peripheral or central [2]. Peripheral NP conditions include: diabetic peripheral neuropathy (DPN), chemotherapy-induced peripheral neuropathy, radicular pain, postsurgical chronic

neuropathic pain, trigeminal neuralgia and postherpetic neuralgia (PHN). Central NP conditions (nociceptive pain) include multiple sclerosis, poststroke pain, spinal cord injury-related pain, and complex regional pain syndrome [2, 3]. NP has a population prevalence of 6.9–10% [4].

Several guidelines for the treatment of NP have been issued (Table 1) [2, 5–7]. First- and second-line treatment recommendations include: gabapentinoids (i.e., gabapentin or pregabalin), tricyclic antidepressants (TCAs), serotonin–norepinephrine reuptake inhibitors (SNRIs), topical lidocaine, topical capsaicin, and opioids. Less than 50% of patients find adequate pain relief, which is due in part to suboptimal efficacy and/or dose-limiting adverse effects (AEs) [8–10]. A large retrospective analysis of a claims database found that 57% of patients with PHN treated with gabapentinoids switched to another therapy and another 34% of patients added a second therapy [10]. Suboptimal dosing may limit efficacy as only 69% of pregabalin patients and 14% of gabapentin patients were successful in being titrated up to a minimal effective dose [10]. In patients who do not achieve adequate pain relief with single first-line therapies, treatment guidelines recommend combining first-line therapies or adding tramadol, a synthetic opioid to the first-line therapy (Fig. 1) (Table 1) [2]. Because first-line therapy leaves so many patients with inadequate pain relief, combination therapy has become more common in clinical practice [8]. Combination therapy can be beneficial when medications are chosen based on differing mechanisms of action, often leading to additive or synergistic therapeutic benefits with enhanced tolerability and safety [8].

Side effects can be a limiting factor when combining drugs. The side effects of agents used to treat NP are listed in Table 2 [11–16]. Systemic agents (tricyclic antidepressants (TCAs), serotonin–norepinephrine reuptake inhibitors (SNRIs), gabapentinoids, and opioids) used in the treatment of NP have central nervous system-related side effects including somnolence, dizziness, sedation, dry mouth, and also have precautions and warnings about their use (Table 2). Lidocaine patches have primarily local dermal side


**Table 1** Summary of NP guidelines

| Guideline source | CDC [7]                                                        | Comprehensive Algorithm on Management of NP 2019 [2]                                | EFNS (European Federation of Neurological Societies) 2010 [5] | NeuPSIG (International Association for the Study of Pain) 2015 [6]             |
|------------------|----------------------------------------------------------------|-------------------------------------------------------------------------------------|---------------------------------------------------------------|--------------------------------------------------------------------------------|
| Indication       | All neuropathic pain                                           | All neuropathic pain                                                                | PHN                                                           | All neuropathic pain                                                           |
| First line       | Gabapentin<br>Pregabalin<br>TCAs<br>SNRIs<br>Topical lidocaine | Gabapentin<br>Pregabalin<br>TCAs<br>SNRIs<br>Topical lidocaine<br>Topical capsaicin | Gabapentin<br>Pregabalin<br>TCAs<br>Lidocaine plasters        | Gabapentin<br>Gabapentin ER<br>Pregabalin<br>Duloxetine<br>Venlafaxine<br>TCAs |
| Second line      |                                                                | Combination of first-line agents<br>Tramadol                                        | Strong opioids<br>Capsaicin                                   | Lidocaine patch<br>Capsaicin patch<br>Tramadol                                 |

effects that are usually mild to moderate and transient (Table 2). Combination therapy using two systemic drugs has the risk of drug–drug interactions or drug–disease interactions and systemic side effects. On the other hand, topical agents have the advantage of minimal systemic exposure, and therefore topical agents can be combined with systemic drugs to achieve an

additive effect with minimal risk of systemic interactions [17].

Recent reviews that used systematic searches have been made to evaluate the effectiveness and safety of combination therapy for NP in adults [8, 18, 19]. The search criteria used for these reviews only allowed for the inclusion of evidence from double-blinded, randomized clinical trials. As there had been no clinical trials



**Fig. 1** Algorithm for the management of chronic NP [2]

**Table 2** Side effects associated with first-line therapies for neuropathic pain

| Medication class        | Major/common side effects                                                              | Precautions                                                                                                                                                                    | References |
|-------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| TCAs                    | Sedation, dry mouth, blurred vision, weight gain, urinary retention                    | Cardiac disease, glaucoma, suicide risk, seizure disorder, concomitant use of tramadol                                                                                         | [11]       |
| SNRIs                   | Nausea, dry mouth, somnolence, constipation, decreased appetite, and hyperhidrosis     | Hepatotoxicity, orthostatic hypotension, serotonin syndrome, severe skin reactions, mania, glaucoma, blood pressure increases, sexual dysfunction, glucose control in diabetes | [12]       |
| Gabapentin              | Sedation, dizziness, peripheral edema                                                  | Renal insufficiency                                                                                                                                                            | [13]       |
| Pregabalin              | Sedation, dizziness, peripheral edema                                                  | Renal insufficiency                                                                                                                                                            | [14]       |
| Opioids                 | Nausea/vomiting, constipation, drowsiness, dizziness, seizures, respiratory depression | History of substance abuse, suicide risk, driving impairment during treatment initiation, seizure disorder, concomitant SSRI/SNRI/TCA use, respiratory depression              | [15]       |
| Topical lidocaine patch | Local erythema, rash                                                                   | None                                                                                                                                                                           | [16]       |

*SSRI* selective serotonin reuptake inhibitors

of combination therapy for NP that included lidocaine patches that were double-blinded and randomized, any evidence from clinical trials for the effectiveness of combination therapy for NP including lidocaine patches was not found or evaluated in these systematic reviews. Lidocaine patches are considered first- or second-line therapy in most guidelines for the treatment of NP (Table 1), thus any evidence for the utility of lidocaine patches for combination therapy of NP would be of interest.

The rationale for this review was: 1—Since monotherapy for NP is effective in less than 50% of cases, there is a need for multimodal combination therapy to adequately treat pain in many patients with NP [8–10] 2—Since using a lidocaine patch in combination therapy for NP has a minimal risk for drug–drug interactions and systemic side effects, the focus of this review was to find if there is evidence from trials that combination therapy of the topical lidocaine patches with systemic agents will have better efficacy and/or less risk of AEs than the combination of two systemic agents; 3—Since

gabapentinoids are one of the most common systemic agents used in first-line NP therapy and topical lidocaine patches are one of the most prevalent topical agent used, we compared the efficacy and side effects of gabapentinoids plus other systemic agents to the use of gabapentinoids plus topical lidocaine patches. The objective of this review was to summarize the safety and efficacy data of three gabapentinoid combinations: gabapentinoid plus opioid, gabapentinoid plus antidepressants (TCAs and SNRIs), and gabapentinoid plus topical lidocaine patches. Additionally, the review aimed to evaluate the benefit–risk ratio of each combination.

## METHODS

Using recently published systematic reviews [8, 18, 19], we identified combination studies of NP involving gabapentinoids plus opioids, or gabapentinoids plus antidepressants. In addition, we searched for and then reviewed publications of

trials involving gabapentinoid plus topical lidocaine patches [17, 20–22].

This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

## RESULTS

Two recent systematic reviews [8, 18] covered combination therapy for neuropathic pain. Neither review includes studies where lidocaine patch was a part of the combination therapy but they provide a wealth of information on studies of combination therapy starting with gabapentinoids followed by opioids or antidepressants.

Two studies were found where combination therapy for NP started with gabapentinoid treatment and lidocaine patches were added as therapy in those patients who did not achieve adequate pain relief with the gabapentinoid therapy alone [17, 20–22].

**Gabapentinoid plus opioid combination studies:** Six combination therapy trials were found where the patients were treated with a gabapentinoid and an opioid [23–28]. These six trials included 931 patients (Table 3). Overall, these six trials gave mixed results on the efficacy of pain relief. Efficacy with combination therapy was superior to monotherapy in four studies [24–27], however there was no difference in efficacy between monotherapy and combination therapy in the other two studies [23, 28]. AEs, particularly dizziness and somnolence, were higher in the combination group in most of these studies and dropouts due to AEs were often higher in the combination groups.

**Gabapentinoid plus antidepressant combination studies:** Three combination therapy trials with 472 patients were examined, where the patients were treated with a gabapentinoid and an antidepressant (Table 4) [29–31]. Two of the studies used antidepressants of the TCA class [29, 31] and one study used an antidepressant of the SNRI class [30]. Combination therapy was superior in efficacy to monotherapy in

two studies [29, 31]. There was no difference between treatments in efficacy in one study [30]. Dropouts due to AEs were higher and dry mouth was more frequent with combinations in one study [29]. Dry mouth AEs were in 60% of patients with combination therapy while only at 17% with gabapentin monotherapy in a second study [31]. There was no difference in treatment-emergent adverse events (TEAEs) between treatment groups in another study [30].

**Gabapentinoid plus lidocaine patch combination studies:** Two studies of gabapentinoid plus lidocaine patch combination therapy were identified [17, 20–22].

In the first study [17], 107 patients with NP and DPN, PHN, or lower back pain (LBP) who had incomplete response to gabapentin monotherapy were treated for 2 weeks with lidocaine patches in addition to continuing the gabapentin therapy. For treatment with the lidocaine patches, up to four lidocaine patches (560 cm<sup>2</sup>) were applied to the area of maximal peripheral pain in for up to 24 h in each 24-h period [17]. Statistically significant ( $p < 0.001$ ) improvements in measures of pain intensity and pain relief (Brief Pain Inventory (BPI) scores for worst pain, least pain, average pain, pain right now, and pain relief) were reported after 2 weeks with the combination therapy compared to baseline measures. Statistically significant ( $p < 0.05$ ) improvements in measures of pain interference with general activity, mood, walking ability, normal work, relationships with others, sleep and enjoyment of life were also noted. The patches were well tolerated and all treatment-related AEs were mild to moderate. There were no indications of any AEs that may have resulted from drug–drug interactions [17].

The second study was presented in three publications [20–22]. It was a two-stage study; the first part was a non-inferiority study comparing pregabalin to the 5% lidocaine patch, and the second stage was a combination therapy study of pregabalin plus the 5% lidocaine patch (Fig. 2 depicts the complete trial design for these studies). For treatment with the lidocaine patches, up to three or four lidocaine patches (depending on the size of the painful area) were applied to the painful area for up to 12 h within each 24-h period [20–22]. In

**Table 3** Summary of gabapentinoid plus opioid combination studies


| Study                | Design                                                  | Indication                  | N   | Treatment                                                              | Analgesic efficacy                                                                                                        | Safety                                                                                                                           |
|----------------------|---------------------------------------------------------|-----------------------------|-----|------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| Baron (2015) [23]    | Randomized, controlled, multicenter trial               | Low back pain (neuropathic) | 313 | 1. Tapentadol PR + pregabalin<br>2. Tapentadol PR                      | No difference                                                                                                             | TEAEs: Dizziness and somnolence higher in combination arm (43/159, 27%) than tapentadol arm (26/154, 17%)                        |
| Dou (2017) [24]      | Randomized, controlled, single-center, cross-over trial | Neuropathic cancer pain     | 40  | 1. Morphine + pregabalin<br>2. Morphine                                | Minimal effective dose of morphine was statistically significantly lowered in combination with pregabalin vs. monotherapy | Combination treatment (pregabalin + morphine) associated with higher frequency of dry mouth and somnolence compared with placebo |
| Caraceni (2004) [25] | Randomized, controlled, multicenter trial               | Neuropathic cancer pain     | 121 | 1. Gabapentin + opioid<br>2. Opioid                                    | Average pain score was statistically significantly reduced in combination arm vs. monotherapy                             | Dropouts due to AEs: 6/80 in the combination group vs. 3/41 in the monotherapy group                                             |
| Gilron (2005) [26]   | Randomized, controlled, single-center, cross-over trial | DPN, PHN                    | 57  | 1. Gabapentin + morphine<br>2. Gabapentin<br>3. Morphine<br>4. Placebo | Mean daily pain score was statistically significantly lower in the combination group vs. monotherapy groups               | Combination groups had higher rates of constipation and dry mouth compared with monotherapy groups                               |

Table 3 continued

| Study             | Design                                    | Indication | N   | Treatment                                  | Analgesic efficacy                                                                            | Safety                                                                                                                                                                                                     |
|-------------------|-------------------------------------------|------------|-----|--------------------------------------------|-----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hanna (2008) [27] | Randomized, controlled, multicenter trial | DPN        | 338 | 1. Gabapentin + oxycodone<br>2. Gabapentin | Pain scores were statistically significantly reduced in the combination group vs. monotherapy | The combination group had higher rates of constipation, nausea, vomiting, dizziness, fatigue and somnolence. The combination group had higher rate of dropouts due to AEs (27/169) vs. monotherapy (9/169) |
| Zin (2010) [28]   | Randomized, controlled, single center     | DPN, PHN   | 62  | 1. Pregabalin + oxycodone<br>2. Pregabalin | No difference                                                                                 | Dropouts because of AEs: 4/29 in the combination group vs. 0/33 in the pregabalin monotherapy group                                                                                                        |

Table 4 Summary of gabapentinoid plus antidepressant studies

| Study               | Design                                               | Indication     | N   | Treatment                                                                  | Analgesic efficacy                                                                                                    | Safety                                                                                                                                                                      |
|---------------------|------------------------------------------------------|----------------|-----|----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Holbech (2015) [29] | Randomized, controlled, multicenter, crossover trial | Polyneuropathy | 73  | 1. Pregabalin + imipramine<br>2. Imipramine<br>3. Pregabalin<br>4. Placebo | The combination arm had lower pain score than monotherapy arms                                                        | Dropouts due to AEs higher on combination arm (7/73) vs. imipramine (3/73), pregabalin (2/73), or placebo (1/73). Frequent AEs include: tiredness, dizziness, and dry mouth |
| Tesfaye (2013) [30] | Randomized, controlled, multicenter trial            | DPN            | 343 | 1. Pregabalin + duloxetine<br>2. Duloxetine<br>3. Pregabalin               | No difference                                                                                                         | No statistically significant differences between treatment groups for TEAE                                                                                                  |
| Gilron (2009) [31]  | Randomized, controlled, single-center trial          | PHN, DPN       | 56  | 1. Gabapentin + nortriptyline<br>2. Nortriptyline<br>3. Gabapentin         | Mean daily pain intensity was statistically significantly lowered during combination treatment vs. either monotherapy | At the maximum tolerated dose, dry mouth was significantly more frequent with nortriptyline or the combination therapy compared to gabapentin alone                         |



**Fig. 2** Study design for the two-stage non-inferiority and combination therapy trial with pregabalin and the 5% lidocaine-medicated plaster of adults with PHN and DPN

[20–22]\*. \*NRS-3 = average pain intensity over the last 3 days measured on the 11-point numerical rating scale (0 = no pain to 10 = worst pain imaginable)

the first stage of the study, 311 patients with DPN or PHN were treated in a randomized, open-label, multicenter, non-inferiority trial with randomization to either pregabalin or to the 5% lidocaine patch for 4 weeks and the results were presented by Baron et al. [21]. In the second stage, patients with inadequate pain relief from either arm of the first part were treated with combination therapy for 8 weeks with lidocaine patches added to those who took pregabalin in the first stage and with pregabalin added to those who used the lidocaine patch in the first stage [22]. Those patients who achieved adequate pain relief in the first stage continued on with monotherapy. The results of the second stage of the study are presented in Baron et al. [22]. A third publication on this trial reported specifically on the results for the patients with DPN in all the stages of the study [20]. In these studies, pain intensity was measured using NRS-3 scale, (11-point scale, 0=no pain, 10=pain as bad as you can imagine). Inadequate pain relief after the first part was defined as patients with NRS-3 scores that were >4 after the first 4 weeks of monotherapy.

In the first stage of the study, which lasted 4 weeks, the randomized non-inferiority trial segment, 66.4% and 61.5% of patients receiving lidocaine patches or pregabalin, respectively, achieved pre-defined responder criteria for pain relief. Further, only 5.8% of patients in the lidocaine group

discontinued due to AEs while 25.5% of patients discontinued due to AEs in the pregabalin group. Although the first stage of this trial was a non-inferiority part, Baron et al. [21] concluded that first-line treatment with the lidocaine patch was more effective than pregabalin for patients with PHN and that the lidocaine patch and pregabalin were comparable and with patients with DPN.

The second, combination therapy, stage of the study continued over the next 8 weeks [22]. The adequate responders continued on their monotherapy regimen (either pregabalin or lidocaine patch) while the inadequate responders of each dosing group were treated with combination therapy. The inadequate responders from the lidocaine group ( $n=57$ ) added pregabalin (LP group) to the existing lidocaine patch therapy and the inadequate responders from the pregabalin group ( $n=44$ ) added lidocaine patches (PL group) to the existing pregabalin therapy [22]. Patients in both combination therapy groups (LP or PL) achieved clinically relevant reductions in pain values with improvements similar between the two groups (~48% reduction in pain intensity). The average NRS-3 scores of the LP group and PL group after the 4 weeks of monotherapy were at 6.1 and 5.7, respectively, before the addition of pregabalin and declined to 3.6 and 4.0, respectively, after the 4 weeks of combination therapy. There were

also improvements in patient treatment satisfaction and patient's global impression of change. AEs were in line with previous reports for the two treatments and combination therapy was generally well tolerated [22].

The second stage continued in the PL group with a 4-week study of the possible down titration of the pregabalin dose [22]. Patients in the PL group who had adequate response to combination therapy (combination therapy patients pregabalin first then with added lidocaine patches) ( $n=31$ ) entered into a 4-week pregabalin down titration phase while continuing on the lidocaine patch (patients were taking 300 or 600 mg/day before the start of the down titration). For the patients with DPN, 20 out of 21 were able to reduce their pregabalin dose by at least 150 mg/day [22]. All ten of the patients with PHN were able to stop the pregabalin part of the combination therapy while maintaining sufficient analgesic efficacy using the lidocaine patch alone [22]. Thus, dose reductions or elimination of pregabalin therapy was achieved with lidocaine patch therapy.

The third publication about this study, Rehm et al. [20], reports the results for only the patients with PHN who were part of the Baron studies above. The patients with PHN who received pregabalin and then had lidocaine patches added for the combination therapy achieved a further 48% reduction in pain intensity comparing the combination therapy with the pregabalin monotherapy baseline [20]. Drug-related AEs occurred in 5.9% of patients with combination treatment (PL), most of them related to pregabalin [20]. The authors concluded that lidocaine 5% patch is at least as effective as pregabalin for pain relief in PHN with a favorable safety profile and a resulting positive benefit–risk ratio [20]. In patients unresponsive to either monotherapy, combination therapy provided additional efficacy and is well tolerated [20].

## DISCUSSION

Topical lidocaine patches as an add-on therapy to gabapentinoids demonstrated clinically relevant reductions of pain in these trials while

AEs were mild or moderate [17, 20–22]. Patients with NP and PHN, DPN or LBP were included in the trials. More tolerable safety profile may be attributed to lack of drug–drug interactions between the topical lidocaine patches and the systemic gabapentinoids and limited systemic drug exposure from lidocaine patches.

The randomized, open-label, non-inferiority phase reported by Baron et al. [21] demonstrating the non-inferiority of lidocaine patches to pregabalin adds evidence of the effectiveness of lidocaine patches as first-line therapy for NP. Down titration studies by Baron et al. [22] and Rehm et al. [20] suggest there can be other benefits from combination therapy with lidocaine patches, including the ability to lower the dose of the gabapentinoid after a period of combination therapy while maintaining efficacy, thus lowering the risk of AEs.

The data from these trials [17, 20–22] provides evidence that lidocaine patches used as add-on therapy to gabapentinoids can be effective in treating NP pain associated with DPN, PHN, and LBP with a minimal additive risk of AEs.

By contrast, data from studies using combination systemic therapies (opioids or antidepressants added to gabapentinoids) demonstrated mixed efficacy results. In each study, there is the concern of increased AEs, and the concern that AEs are increasing because of drug–drug interactions and additive systemic AEs. The reviews of Balanaser et al. [18] and Afonso et al. [8] took an intensive look at combination therapies for the treatment of NP. Neither systematic review found evidence that supported recommendations for regular use of any specific combination, with drug–drug interactions between the systemic agents as a limiting factor [8, 18].

The lidocaine patch studies cited here have limitations. These include that the combination stage of each study is not randomized, and there is no placebo control [17, 20–22]. Instead of randomized clinical trials, the patients in these studies were treated similarly to real-world practice. First, one drug is trialed, and in patients who get inadequate pain relief, multi-modal combination therapy is tried. With this scenario, in the lidocaine patch add-on trials, add-on therapy with lidocaine patches demonstrated an additional ~48% reduction in pain relief.

**Table 5** Summary of gabapentinoid plus lidocaine patch studies

| Study                                     | Design                                                                                                                 | Indication    | N   | Treatment                                        | Analgesic efficacy                                                                                                                                                                                                                           | Safety                                                                                                                                                                |
|-------------------------------------------|------------------------------------------------------------------------------------------------------------------------|---------------|-----|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| White (2003) [16]                         | Open-label, non-randomized, multicenter trial                                                                          | PHN, DPN, LBP | 107 | 1. Gabapentin + lidocaine patch                  | BPI scores for worst, least, average, pain right now, and pain relief scores were statistically significantly lower compared with baseline                                                                                                   | The most frequently reported treatment-related AEs were somnolence (1.9%), paresthesia (1.9%), and dermatitis (1.9%). All treatment-related AEs were mild to moderate |
| Baron (2009A) [20],<br>Baron (2009B) [21] | Two-stage adaptive, randomized, open-label, multicenter, non-inferiority study followed by a combination therapy stage | PHN, DPN      | 311 | 1. Pregabalin + lidocaine patch<br>2. Pregabalin | Combination therapy resulted in clinically relevant reductions in pain values in addition to improvements achieved during the 4 weeks of pregabalin monotherapy. Considerable improvements in patients' treatment satisfaction were reported | Combination therapy was generally well tolerated                                                                                                                      |
| Rehm (2010) [20]                          | Randomized, open-label, multicenter, non-inferiority study                                                             | PHN           | 98  | 1. Pregabalin + lidocaine patch<br>2. Pregabalin | 49% reduction in pain intensity with combination treatment (vs. monotherapy baseline)                                                                                                                                                        | Drug-related AEs occurred in 5.9% of patients with combination treatment (PL), most of them related to pregabalin                                                     |

These two trials provide evidence that combination therapy with lidocaine patches can be effective against NP that occurs with conditions such as DPN, PHN, and LBP. This review and the cited studies using lidocaine patches as add-on therapy in NP [17, 20–22] are all sponsored and funded by companies producing and marketing lidocaine patches.

Looking beyond multimodal therapy with lidocaine patches involving gabapentinoids, two other studies support the use of lidocaine patches as add-on therapy in NP [32, 33]. Tsai et al. found in an open-label, single-arm trial that lidocaine topical patches reduced pain intensity in neuropathic cancer patients already receiving opioid treatment [32]. Martini et al., in a retrospective study of 130 patients in their database, found that the 5% lidocaine-medicated plaster was efficacious in patients with localized NP poorly responsive to pharmacological therapy [33].

More evidence for the benefits of multimodal therapy with lidocaine patches and plasters comes from a study by Li et al. that analyzed the lidocaine plaster in combination with gabapentin in the treatment of herpes zoster neuralgia [34]. Pain was reduced in the combination group compared to either monotherapy. They concluded that the combination had better analgesic effects in the treatment of herpes zoster neuralgia with fewer incidences of AEs and helped in some cases to reduce the dosage of gabapentin [34].

Despite the limitations, the studies strongly suggest that lidocaine patches are an efficacious, safe, and well-tolerated add-on treatment to gabapentinoids. More studies on the use of lidocaine patches as an add-on therapy for the treatment of NP may be valuable to pursue (see Table 5).

Lidocaine patches come in multiple forms that are bioequivalent, meaning they deliver the same amount of lidocaine to the skin (Table 6) [35–37]. They can differ in the amount of lidocaine in the patch, the percent of the lidocaine delivered, the thickness of the patch, the adhesive used, and the amount of adhesive [35–37]. They can also differ in their adhesive properties [38]. The generic lidocaine patches are similar to the Lidoderm patch in the amount and percent of lidocaine in the patch, the thickness of the patch, and the adhesive used. The lidocaine topical system 1.8% differs in many ways from these other patches. It is flexible and has been shown to adhere substantially better than the 5% lidocaine patches while delivering a bioequivalent amount of lidocaine [38]. Due to their superior adhesive properties, the lidocaine topical systems 1.8% provide more consistent drug delivery and greater utility in real-world settings [39–41].

**Table 6** Characteristics and composition of prescription lidocaine topical formulations

| Patch                             | Bioequivalent to Lidoderm patch | Design | Lidocaine | Lidocaine (mg) | Adhesive mix (g) | Relative thickness of DIA layer <sup>a</sup> | Adhesive                        |
|-----------------------------------|---------------------------------|--------|-----------|----------------|------------------|----------------------------------------------|---------------------------------|
| Lidoderm [36]                     |                                 | DIA    | 5%        | 700            | 14               | 1.0                                          | Acrylic-based hydrogel          |
| ZTlido [16]                       | Bioequivalent                   | DIA    | 1.8%      | 36             | 2.0              | 0.14                                         | Polyisobutylene adhesive matrix |
| Generic 5% lidocaine patches [37] | Bioequivalent                   | DIA    | 5%        | 700            | 14               | 1.0                                          | Acrylic-based hydrogel          |

*DIA* drug-in-adhesive

<sup>a</sup>Assumes density of DIA layers are approximately the same, as these patches are all the same size, 10 × 14 cm, the thickness of the DIA layer will be proportional to the amount of adhesive mix used

## CONCLUSIONS

In the studies reviewed, combinations of systemic agents (gabapentinoid plus opioid or antidepressant) were associated with increased AEs and dropouts while improvement in efficacy was inconsistent. Combinations of systemic gabapentinoids plus topical lidocaine patches can improve efficacy with minimal additional AEs. Topical lidocaine patches, which are associated with minimal systemic adverse effects and have demonstrated benefits in various neuropathic pain (NP) conditions, can enhance the likelihood of achieving meaningful pain relief when used as adjuvant therapy.

## ACKNOWLEDGEMENTS

### *Medical Writing and Editorial Assistance.*

Medical writing and editorial assistance in the preparation of this article was funded by SciLex Pharmaceuticals Inc. Palo Alto, CA, and was provided by James D. Bergstrom, PhD of Mountain Stream Communications, Hillsborough, NJ, USA.

### *Author Contributions.*

Sri Nalamachu, Elaine K. Chan, and Dmitri Lissin developed the concepts for this article. The literature searches and analysis were performed by Sri Nalamachu, Elaine K. Chan, and Wendy Borgersen. Sri Nalamachu, Elaine K. Chan, Wendy Borgersen, Dmitri Lissin, Theresa Mallick-Searle<sup>2</sup>, and Jeremy Adler drafted and/or critically revised the work.

### *Funding.*

Funding for this review, research, and the journal's Rapid Service Fee was provided by Scilex Pharmaceuticals Inc., Palo Alto, CA, USA.

### *Data Availability.*

All data generated or analyzed during this study are included in this published article.

## Declarations

**Conflict of Interest.** Sri Nalamachu is a paid consultant for Scilex Holdings. Sri Nalamachu is an Editorial Board member of Pain and Therapy. Sri Nalamachu was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Elaine K. Chan, Wendy Borgersen, and Dmitri Lissin are employees of Scilex Holdings. Jeremy Adler is a paid consultant for Averitas, Collegium Pharmaceuticals.

**Ethical Approval.** This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

**Open Access.** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

## REFERENCES

1. Treede R-D, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain. Redefinition and a grading system for clinical and research purposes. *Neurology*. 2008;70:1630–5.
2. Bates D, Schultheis BC, Hanes MC, Jolly SM, et al. A comprehensive algorithm for management of neuropathic pain. *Pain Med*. 2019;20:S2–12.

3. Szok D, Tajti J, Nyári A, Vécsei L. Therapeutic approaches for peripheral and central neuropathic pain. *Behav Neurol*. 2019. <https://doi.org/10.1155/2019/8685954>.
4. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. *Pain*. 2014;155:654–62.
5. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of pain: 2010 revision. *Eur J Neurology*. 2010;17:1113–23.
6. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations. *Lancet Neurol*. 2015;14:162–73.
7. Center for Disease Control. Nonopioid treatments for chronic pain. [https://stacks.cdc.gov/view/cdc/38483/cdc\\_38483\\_DS1.pdf](https://stacks.cdc.gov/view/cdc/38483/cdc_38483_DS1.pdf).
8. Afonso AS, Carnaval T, Sebastião VC. Combination therapy for neuropathic pain: A review of recent evidence. *J Clin Med*. 2021;10:3533.
9. Finnerup NB, Haroutounian S, Kamerman P, Baron R, et al. Neuropathic pain: an updated grading system for research and clinical practice. *Pain*. 2016;157:1599–606.
10. Johnson P, Becker L, Halpern SM. Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. *Clinical Drug Invest*. 2013;33:35–44.
11. Tofranil-PM™ (imipramine pamoate) Prescribing Information. 2014; Mallinckrodt Inc. Hazelwood, MO 63042 USA
12. Cymbalta (duloxetine delayed-release) Prescribing Information. 2017; Lilly USA, LLC Indianapolis, IN 46285, USA
13. Neurontin (Gabapentin) Prescribing Information. 2009; Parke-Davis, a division of Pfizer, Inc. NY, NY 10017
14. Lyrica (Pregabalin) Capsules, Prescribing Information. 2018; Parke-Davis, Division of Pfizer Inc., NY, NY 10017.
15. Oxycontin® (oxycodone hydrochloride) extended-release tablets. Prescribing Information. 2021; Purdue Pharma L.P. Stamford, CT 06901–3431
16. ZTLIDO™ (lidocaine topical system) Prescribing information. 2018; Scilex Pharmaceuticals Inc; San Diego, CA
17. White WT, Patel N, Drass M, Nalamachu S. Lidocaine patch 5% with systemic analgesics such as gabapentin: A rational polypharmacy approach for the treatment of chronic pain. *Pain Med*. 2003;4:321–30.
18. Balanaser M, Carley M, Baron R, Finnerup NB, et al. Combination pharmacotherapy for the treatment of neuropathic pain in adults: systematic review and meta-analysis. *Pain*. 2022;164:230–51.
19. Chaparro LE, Wien PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults (Review). *Cochrane Database Syst Rev*. 2012. <https://doi.org/10.1002/14651858.CD008943.pub2>.
20. Rehm S, Binder A, Baron R. Post-herpetic neuralgia: 5% lidocaine-medicated plaster, pregabalin, or a combination of both: a randomized, open, clinical effectiveness study. *Curr Med Res Opin*. 2010;26:1607–19.
21. Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. 5% lidocaine-medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two stage RCT study. *Curr Med Res Opin*. 2009;25:1663–76.
22. Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. Efficacy and safety of combination therapy with 5% lidocaine-medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. *Curr Med Res Opin*. 2009;25:1677–87.
23. Baron R, Martin-Mola E, Müller M, Dubois C, Falke D, Steigerwald I. Effectiveness and safety of tapentadol prolonged release (PR) versus a combination of tapentadol PR and pregabalin for the management of severe, chronic low back pain with a neuropathic component: a randomized, double-blind, phase 3b study. *Pain Pract*. 2015;15:455–70.
24. Dou Z, Jiang Z, Zhong J. Efficacy and safety of pregabalin in patients with neuropathic cancer pain undergoing morphine therapy. *Asia-Pac J Clin Oncology*. 2017;13:357–64.
25. Caraceni A, Zecca E, Bonezzi C, Arcuri E, Tur RY, Maltoni M, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the gabapentin cancer pain study group. *J Clin Oncology*. 2004;22:2909–17.
26. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RI. Morphine, gabapentin or their combination for neuropathic pain. *New Engl J Med*. 2005;352:1324–34.

27. Hanna M, O'Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. *Eur J Pain*. 2008;12:804–13.
28. Zin CS, Nissen LM, O'Callaghan JP, Duffull SB, Smith MT, Brendan JM. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. *J Pain*. 2010;11:462–71.
29. Holbech JV, Bach FW, Finnerup NB, Brosen K, Jensen TS, Sindrup SH. Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial. *Pain*. 2015;156:958–66.
30. Tesfaye S, Wilhelm S, Lledo A, Schacht A, Tölle T, Bouhassira D, et al. Duloxetine and pregabalin: High-dose monotherapy or their combination: the “COMBO-DN study” – a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. *Pain*. 2013;154:2616–25.
31. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden R. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomized controlled crossover trial. *Lancet*. 2009;374:1252–61.
32. Tsai J-H, Liu I-T, Su P-F, Huang Y-T, Chiu G-L, Chen Y-Y, et al. Lidocaine transdermal patches reduced pain intensity in neuropathic cancer patients already receiving opioid treatment. *BMC Palliat Care*. 2023;22:4. <https://doi.org/10.1186/s12904-023-01126-3>.
33. Martini A, Del Balzo G, Schweiger V, Zanzotti M, Picelli A, Parolini M, et al. Efficacy of lidocaine 5% medicated plaster (VERSATIS®) in patients with localized neuropathic pain poorly responsive to pharmacological therapy. *Minerva Med*. 2018;109:344–51.
34. Li J, Huang Y, Lin J. Efficacy analysis of lidocaine plaster combined with gabapentin in the treatment of herpes zoster neuralgia. *Zhonghua Yi Xue Za Zhi*. 2022;102:3186–91.
35. Nalamachu S, Gudín J. Characteristics of analgesic patch formulations. *J Pain Res*. 2020;13:2343–54.
36. Lidoderm (Lidocaine Patch 5%) Prescribing Information. 2015; Endo Pharmaceuticals Inc. Malvern, PA.
37. Lidocaine (Lidocaine Patch) Prescribing Information. 2018; Mylan Pharmaceuticals Inc. Morgantown, WV.
38. Gudín J, Webster LR, Greuber E, Vought K, Patel K, Kuritzky L. Open-label adhesion performance studies of a new lidocaine topical system 1.8% versus lidocaine patches 5% and lidocaine-medicated plaster 5% in healthy subjects. *J Pain Res*. 2021;14:513–26.
39. US Food and Drug Administration. Guidance for Industry. Assessing adhesion with transdermal and topical delivery systems for ANDAs, October 2018. Accessed June 17, 2019.
40. Fudin J, Wegrzyn EL, Greuber E, et al. A randomized, crossover, pharmacokinetic and adhesion performance study of a lidocaine topical system 1.8% during physical activity and heat treatment in healthy subjects. *J Pain Res*. 2020;13:1359–67.
41. Vought K, Greuber E, Patel K, Argoff C, Lissin DJA. Randomized, crossover, adhesion performance and pharmacokinetic study of a lidocaine topical system under conditions of water exposure in healthy subjects. *Pain Res*. 2021;14:2459–67.